Clinical Trial Update: PROCLAIM: CX-072-002: Study of PD-L1 Probody Therapeutic CX-072 in Combination With Other Anticancer Therapy in Adults With Solid Tumors [Phase 2]

View source ↗

Summary

Phase 2 study of the PD-L1 Probody therapeutic CX-072 in combination with other anticancer therapy in adults with solid tumors, including unresectable or metast…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Melanoma
• Solid Tumor

Drugs mentioned

• CX-072

Snippet

Sponsor: CytomX Therapeutics | Conditions: Solid Tumor, Unresectable or Metastatic Melanoma | Phase 2 | Status: TERMINATED | Results posted: 2021-12-01